Decline in forced vital capacity as a surrogate for mortality in patients with pulmonary fibrosis.

Data from clinical trials in subjects with pulmonary fibrosis of diverse aetiology demonstrate a strong association between decline in FVC % predicted and mortality over 52 weeks, supporting FVC decline as a surrogate for mortality in these patients.